 RADNOR, Pa., Sept. 29, 2021 PRNewswire -- NRx Pharmaceuticals NRx NASDAQ: NRXP, a clinical stage, biopharmaceutical company today provided a safety update on ZYESAMITM aviptadil which is being tested in the ACTIV-3b Critical Care Phase 3 study sponsored by the National Institutes of Health. 